Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 1. Differential expression and phosphoryla tion of STAT1 in eosinophils from allergic and healthy non-allergic donors. (A) Purified eosino phils from allergic (n = 10) and healthy donors (n = 12) were fixed and permeabilized, stained with the respective isotype control or specific antibodies against total-STAT1 and phospho-STAT1 and measured by flow cytometry. Data were analyzed as fold increase in fluorescence intensity with respect to the isotype control and reported as phospho-STAT1/ total-STAT1 (mean ± SEM). ** P < 0.01; Student’s t-test. (B-D) Purified eosinophils from healthy donors were pretreated with (B) vehicle (n = 7), (C) bar icitinib (BARI, 200 nM, n = 6) or (D) tofacitinib (TOFA, 200 nM, n = 6) for 30 min at 37 ◦C, stimu lated with vehicle or IL-5 (300 pM) for 10 min at 37 ◦C, fixed and permeabilized, stained with isotype control or a phospho-STAT1 antibody and analyzed by flow cytometry. Data are expressed as fold in crease in fluorescence intensity with respect to the isotype control (mean ± SEM). * P < 0.05; Student’s t-test.

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Quantitative Proteomics, Purification, Staining, Control, Flow Cytometry, Fluorescence

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 2. Baricitinib and tofacitinib similarly inhibit eosinophil differentiation and JAK1/2 activation. Bone marrow cells were collected from the femurs and tibiae of three female BALB/c mice and cultured at 106/mL in media supplemented with 100 ng/mL SCF and 100 ng/mL FLT3L from day 0 to day 4. On day 4, media were replaced with media containing 10 ng/mL IL-5 supplemented with or without baricitinib (BARI, 200 nM) or tofacitinib (TOFA, 200 nM). (A) Total cells, (B) Siglec F positive cells and (C) CCR3 positive cells were enumerated by flow cytometry on the indicated days. On day 12 (D) JAK1 and (E) JAK2 phosphorylation was measured by flow cytometric intracellular staining. Data are shown as mean ± SEM from 3 independent experiments, ** P < 0.01, *** P < 0.005; (A-C) two-way ANOVA and (D and E) one- way ANOVA.

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Activation Assay, Cell Culture, Flow Cytometry, Phospho-proteomics, Staining

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 3. Effects of baricitinib and tofacitinib on eosinophil migratory responsiveness. (A) Purified eosinophils were seeded on L-lysine coated chamber slides and pretreated with baricitinib (200 nM), tofacitinib (200 nM) or vehicle for 30 min at room temperature. F-actin polymerization was induced by stimulation with IL- 5 (1 nM) at 37 ◦C for 15 min. Adherent cells were fixed, permeabilized and blocked prior to F-actin staining with Phalloidin-Texas Red. Slides were mounted with mounting media with DAPI and fluorescence images were taken by an Olympus IX70 microscope connected with a Hamamatsu ORCA-ER digital camera. Olympus xcellence® imaging analysis software 1.1 was used for acquiring images. Representative pictures of 4 independent experiments are shown. (B-E) Purified eosinophils (n = 4–16) were pretreated with vehicle, baricitinib (BARI, 200 nM or 500 nM) (B and D) or tofacitinib (TOFA, 200 nM or 500 nM) (C and E) for 30 min at 37 ◦C and were allowed to migrate towards eosinophil chemoattractants: IL-5 300 pM, complement 5a 10 nM, CCL11 10 nM and PGD2 30 nM for 60 min in a 48-well micro- Boyden chamber. Migrated cells were enumerated by flow cytometry (BD FACSCanto II, high flow-rate for 30 s). Data are shown as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.005; Student’s t-test.

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Purification, Staining, Fluorescence, Microscopy, Imaging, Software, Flow Cytometry

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 4. Effects of baricitinib and tofacitinib on neutrophil chemotaxis. PMNL (n = 14) were pre treated with vehicle, baricitinib (BARI, 500 nM) or tofacitinib (TOFA, 500 nM) for 30 min at 37 ◦C and were allowed to migrate towards neutrophil chemo attractants: IL-8 (10 nM) and complement 5a (10 nM) for 60 min in a 48-well micro-Boyden chamber. Migrated cells were enumerated by flow cytometry (BD FACSCanto II, high flow-rate for 30 min). Data are shown as mean ± SEM. * P < 0.05; Student’s t- test.

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Chemotaxis Assay, Flow Cytometry

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 5. Effects of baricitinib and tofacitinib on eosinophil ROS production. Purified eosinophils were pretreated with vehicle, baricitinib (BARI, 500 nM) or tofacitinib (TOFA, 500 nM) for 30 min at 37 ◦C and ROS production was induced by IL-5 (A, n = 4–8), complement 5a (B, n = 6), CCL11 (C, n = 5–8) and PGD2 (D, n = 7–9). ROS production was detected by flow cytometry using a dihydrorhodamin-123 based assay. Data are expressed as geometric mean fluorescence intensity (MFI) and shown as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.005; two-way ANOVA.

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Purification, Flow Cytometry, Fluorescence

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 6. Effects of baricitinib and tofacitinib on eosinophil phagocytosis and degranulation. Purified eosinophils were pretreated with vehicle, baricitinib (500 nM and 2.5 µM) (A, n = 4) or tofacitinib (500 nM and 2.5 µM) (B, n = 4) for 30 min at 37 ◦C, incubated with opsonized Escherichia coli-FITC and analyzed by flow cytometry. Phagocytosis is presented as the percentage of E. coli-FITC-positive eosinophils. Data are shown as mean ± SEM. * P < 0.05, ** P < 0.01; One-way ANOVA. (C) Purified eosinophils were pretreated with vehicle, baricitinib or tofacitinib (500 nM) for 30 min at 37 ◦C and then stimulated with complement 5a for 30 min at 37 ◦C. The release of EPO activity into the supernatant was determined by photometry. Data were expressed as a percentage of the vehicle response (unstimulated) and are shown as the mean ± SEM; n = 14. Two-way ANOVA.

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Purification, Incubation, Flow Cytometry, Activity Assay

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 7. Effects of baricitinib and tofacitinib on eosinophil apoptosis. Purified eosinophils were cultured in vehicle or IL-5 100 pM-treated medium, supplemented with or without baricitinib (BARI, 500 nM) or tofacitinib (TOFA, 500 nM) for 18 h. Apoptosis and necrosis were detected by flow cytometry using FITC-annexin-V/ propidium iodide (PI). Annexin/PI double-negative cells were identified as live cells (A), annexin positive/PI negative cells as early apoptotic cells (B), annexin/PI double-positive cells as late apoptotic cells and annexin negative/PI positive cells as necrotic cells (D). Data are expressed as % of total cells and shown as mean ± SEM of 11 independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.005; two-way ANOVA.

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Purification, Cell Culture, Flow Cytometry

Journal: Biochemical pharmacology

Article Title: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.

doi: 10.1016/j.bcp.2021.114690

Figure Lengend Snippet: Fig. 8. Effects of baricitinib and tofacitinib on HDM-induced lung inflammation and airway hyperresponsiveness. (A) On day 1, eight-week-old female BALB/c mice were sensitized intranasally with 1 µg HDM and challenged by intranasal application of 10 µg HDM per day from day 7 to 12. From day 8 to 14 mice received intragastric applications of tofacitinib (TOFA, 50 µmol, twice a day) and baricitinib (BARI, 50 µmol, once a day). (B) Gating strategy for lung single cell suspensions. After single cell and CD45pos gating, eosinophils were identified as CD11cneg/Siglec Fpos and alveolar macrophages as CD11cpos/Siglec Fpos cells. CD11c/ Siglec F double negative cells were characterized as CD11bpos/Ly6Gpos neutrophils, CD11bpos/Ly6Gneg monocytes and FSC/SSClow CD11bneg/Ly6Gneg lymphocytes. On day 15, (C) lungs, (D) spleens, and (E) bone marrow were taken from six mice per group and inflammatory cells were analyzed by flow cytometry: Total CD45pos

Article Snippet: In some experiments eosinophils from healthy donors were pretreated with vehicle, baricitinib (200 nM; TargetMol) or tofacitinib (200 nM; TargetMol) for 30 min at 37 ◦C and stimulated with vehicle or IL-5 (100 pM) for 10 min at 37 ◦C prior to the staining.

Techniques: Single Cell, Flow Cytometry

Journal: Journal of pharmaceutical analysis

Article Title: Unveiling the role of Pafah1b3 in liver fibrosis: A novel mechanism revealed.

doi: 10.1016/j.jpha.2024.101158

Figure Lengend Snippet: Fig. 4. Platelet-activating factor acetylhydrolase 1B3 (Pafah1b3) enhances transforming growth factor-b (TGF-b) signaling through interaction with mothers against decapentaplegic homolog 7 (SMAD7). (A) Protein expression of phosphorylation-SMAD3 (p-SMAD3), SMAD3, p-SMAD2, SMAD2, and PAFAH1B3 in 293T cells. (B, C) Co-immunoprecipitation (Co-IP) analysis: immunoprecipitation with anti-HA (B) and anti-Flag (C) antibody in 293T cells. (D) Co-IP analysis: immunoprecipitation with anti-HA antibody in TGF-b1 treated-293T cells. (E) Pull-down assay. (F) 293T cells were transfected with hemagglutinin (HA)-Pafah1b3 and Flag-SMAD7 and stained with antibodies against HA and Flag. Co-location between PAFAH1B3 (green) and SMAD7 (red) in 293T cells. The nucleus appears blue after 40,6-diamidino-2-phenylindole (DAPI) staining. The yellow indicates co-location of SMAD7 and PAFAH1B3. (G) Human SMAD7 domains. (H) Co-IP analysis in 293T cells transfected with HA-Pafah1b3 and different domains of SMAD7. (I) Molecular docking analysis. (J) Co-IP analysis of 293T cells transfected with Flag-SMAD7 and HA-Pafah1b3 mutants. (K) Protein expression of p-SMAD3, SMAD3, p-SMAD2, SMAD2, and PAFAH1B3 in 293T cells transfected with HA-Pafah1b3 mutants. ***P < 0.001. NC: negative control; shRNA: short hairpin RNA; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; ND: N-terminal domain; MH2: mad homologous 2 domain; WT: wild type.

Article Snippet: Cells received specific treatments, including TGF-b1 (CM088 and CM057; Chamot Biotechnology Co., Ltd., Shanghai, China), MG132 (5 mM in dimethyl sulfoxide (DMSO); T2154; TargetMol Chemicals Inc., Shanghai, China), and cycloheximide (20 mg/mL in DMSO; 2112S; Cell Signaling Technology, Shanghai, China).

Techniques: Expressing, Phospho-proteomics, Immunoprecipitation, Co-Immunoprecipitation Assay, Pull Down Assay, Transfection, Staining, Negative Control, shRNA

Journal: Journal of Pharmaceutical Analysis

Article Title: Effect of plasma surface treatment of poly(dimethylsiloxane) on the permeation of pharmaceutical compounds

doi: 10.1016/j.jpha.2017.05.003

Figure Lengend Snippet: Total cumulative amount of compound permeated after 6 h through unmodified and plasma-treated membrane, also expressed as a percentage reduction (%). Polar surface area (PSA) values were calculated using Chemspider ( www.chemspider.com ).

Article Snippet: Sixteen model compounds were analysed using a Franz-type, bespoke, diffusion cell system with a diffusional area of 0.64 cm 2 : aminopyrine (Fisher Scientific, Loughborough, UK, ≥ 97%), benzoic acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), caffeine (Sigma Aldrich, Dorset, UK, ≥ 99%), ethyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 99%), ethyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK, > 98%), ibuprofen (BASF, ≥ 99%), lidocaine (Sigma Aldrich, Dorset, UK, ≥ 98%), methyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 98%), methyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK, ≥ 98%), propyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 99%), propyl 4-aminobenzoate (Alfa Aesar, Lancashire, UK, 98%), flurbiprofen (Tokyo Chemical Industry Ltd, > 98%), diclofenac (Tokyo Chemical Industry Ltd, > 98%), ketoprofen (Tokyo Chemicals Industry Ltd, > 98%), acetyl salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99%) and salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), all as saturated solutions placed in the donor phase.

Techniques: Clinical Proteomics, Membrane

Journal: Journal of Pharmaceutical Analysis

Article Title: Effect of plasma surface treatment of poly(dimethylsiloxane) on the permeation of pharmaceutical compounds

doi: 10.1016/j.jpha.2017.05.003

Figure Lengend Snippet: Experimental membrane permeability ( K p ) values (× 10 −4 ) for both standard PDMS membrane and plasma-treated membrane, presented alongside literature permeability data [41] , [42] , [43] , [44] , [45] . All results are expressed as the mean ± S.D. ( n = 3).

Article Snippet: Sixteen model compounds were analysed using a Franz-type, bespoke, diffusion cell system with a diffusional area of 0.64 cm 2 : aminopyrine (Fisher Scientific, Loughborough, UK, ≥ 97%), benzoic acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), caffeine (Sigma Aldrich, Dorset, UK, ≥ 99%), ethyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 99%), ethyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK, > 98%), ibuprofen (BASF, ≥ 99%), lidocaine (Sigma Aldrich, Dorset, UK, ≥ 98%), methyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 98%), methyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK, ≥ 98%), propyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 99%), propyl 4-aminobenzoate (Alfa Aesar, Lancashire, UK, 98%), flurbiprofen (Tokyo Chemical Industry Ltd, > 98%), diclofenac (Tokyo Chemical Industry Ltd, > 98%), ketoprofen (Tokyo Chemicals Industry Ltd, > 98%), acetyl salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99%) and salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), all as saturated solutions placed in the donor phase.

Techniques: Membrane, Permeability, Clinical Proteomics

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Difference between massively parallel shotgun sequencing (MPSS) and targeted massively parallel sequencing (TMPS). Genomics‐based non‐invasive prenatal testing (gNIPT) aims to count the number of copies of DNA fragments from the chromosomes of interest (chromosome 21 (Chrom. 21) in this example) present in circulating cell‐free DNA (ccfDNA) from a pregnant woman, relative to a reference set of chromosomes (Ref. Chrom.). DNA fragments circulating in maternal blood in the case of a euploid (left) and aneuploid (right) pregnancy are illustrated (top). MPSS produces a large number of sequence reads from all chromosomes while TMPS generates a larger proportion of reads from the chromosomes of interest (bottom). In both methods, sequence reads can be used to detect a slight excess of fetal genomic material coming from the chromosome of interest. Figure was created by FR.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Reported accuracy of commercially available genomics‐based non‐invasive prenatal tests a

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Current clinical pathway and three proposed uses of genomics‐based non‐invasive prenatal testing (gNIPT). Currently (on the left), pregnant women can have a prenatal screening test consisting of biomarkers or ultrasound, or both. For high‐risk pregnant women, an invasive diagnostic test (karyotyping) is offered. In the present review, we propose 3 different clinical pathways. First, gNIPT could be used as a triage test, to decide which pregnant women should receive further testing. Second, gNIPT could be used to replace current prenatal screening tests. Finally, gNIPT could be used to replace current invasive diagnostic tests (if diagnostic performance permits). At any point in a clinical pathway, a pregnant woman may decide not to proceed with other tests (not shown in the figure). Figure was designed by CL, JB, MB and YT.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Diagnostic Assay

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Characteristics of included studies by type of gNIPT

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Multiplexing, Clinical Proteomics, Sequencing, Multiplex Assay, Next-Generation Sequencing, Biomarker Discovery, Software

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Performance of gNIPT for detection of T13

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Manufacturers of gNIPT used in the included studies by prior risk of fetal aneuploidy

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Reasons for patient exclusion

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Amplification, Sequencing, Control, Sampling, Clinical Proteomics, Biomarker Discovery

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Proportion of pregnant women with a reference standard and assay failure during gNIPT process

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Sampling

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Performance of gNIPT for detection of 45,X

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Performance of gNIPT for detection of autosomes aneuploidies (T21, T18 and T13 combined)

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Performance of gNIPT for detection of sex chromosome aneuploidies (45,X, 47,XXX, 47,XXY and 47,XYY combined) a

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Risk of bias and applicability concerns summary: review authors' judgements about each domain for each study included for targeted massively parallel sequencing (TMPS).

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Risk of bias and applicability concerns (all tests included): review authors' judgements about each domains presented as percentages across included studies. MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Summary characteristics of included studies

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Diagnostic Assay, Shotgun Sequencing, Sequencing, Sampling, Selection

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Performance of gNIPT for detection of T21

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Performance of gNIPT for detection of T18

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for T21 in unselected pregnant women undergoing aneuploidy screening. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for T21 in pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for T18 in pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for T13 in pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for 45,X in pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for 47,XXX, 47,XXY and 47,XYY in pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Data for 47,XXX, 47,XXY and 47,XYY according to the prior risk of fetal aneuploidy and gNIPT approach

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for autosomes (T21, T18 and T13 combined) in unselected pregnant women undergoing aneuploidy screening. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Subgroup analyses of MPSS and TMPS (type of pregnancy and gestational age)

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for autosomes (T21, T18 and T13) in pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined) in pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of traditional screening tests for T21, T18 and T13 in unselected pregnant women undergoing aneuploidy screening. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of comparative studies of TMPS and traditional screening tests for autosomes (T21, T18 and T13 combined) in unselected pregnant women undergoing aneuploidy screening. FN: false negative, FP: false positive, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Direct comparisons of gNIPT and traditional screening tests for autosomes (T21, T18 and T13 combined) in unselected population of pregnant women undergoing aneuploidy screening

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of traditional screening tests for autosomes (T21, T18 and T13 combined) in pregnant women with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for autosomes (T21, T18 and T13 combined) in pregnant women with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for T21, T18 or T13 in pregnant women with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined) in pregnant women with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Forest plot of MPSS and TMPS for 45,X, 47,XXY or 47,XYY in pregnant women with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques: Shotgun Sequencing, Sequencing

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Sensitivity analyses

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS T21.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS T18.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS T13.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS 45,X.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS 47,XXX.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS 47,XXY.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS 47,XYY.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS all 7 aneuploidies.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS, autosomes.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: TMPS, SCA.

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women

doi: 10.1002/14651858.CD011767.pub2

Figure Lengend Snippet: Data tables by test

Article Snippet: Index and comparator tests , gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health..

Techniques:

Journal: Frontiers in Plant Science

Article Title: Improving the Identification and Coverage of Plant Transmembrane Proteins in Medicago Using Bottom–Up Proteomics

doi: 10.3389/fpls.2020.595726

Figure Lengend Snippet: Distribution of proteins identified after applying the FA-CTLC or UR-TLC methods to Medicago microsomal membrane (MM) preparations from three biological repeats based on transmembrane domain (TMD) number and grand average of hydropathy (GRAVY) score. (A) The proteins identified after analyzing the UR-TLC- or FA-CTLC-treated samples from three biological repeats were submitted to the TMHMM server. The total predicted number of transmembrane protein (TMP) groups in the UR-TLC and FA-CTLC samples was 2,817 (35.45%) and 2,784 (39.11%), respectively. The predicted TMD distribution of the Medicago proteins in the UniProt database is shown in the inset panel as a comparison. There were 23.26% proteins predicted to be TMPs. * p ≤ 0.05, ** p ≤ 0.01 (two-tail Student’s t –test). Error bars = standard error, n = 3. (B) The GRAVY scores were calculated from the proteins identified after analyzing the UR-TLC or FA-CTLC base on the previous published literature. Approximately 20% of proteins identified by FA-CTLC displayed a GRAVY score greater than zero and 17% of proteins identified by UR-TLC. Proteins with a hydrophobicity scores above 0 are more likely to be TMPs.

Article Snippet: TMPs from Medicago have a variable number of TMDs that range from 1 to over 30.

Techniques: Membrane, Comparison